Exelixis (EXEL) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exelixis (EXEL) has outperformed Repligen (RGEN) over the past year, gaining 52.7% versus a gain of 8.6%. Over five years, EXEL leads with a +170.5% price change compared with -38.6% for RGEN. Exelixis is the larger company by market cap ($14.62 billion vs $10.40 billion), about 1.4 times the size, while Repligen is growing revenue faster (+16.4% vs +7.0%).
On valuation, Exelixis trades at a lower forward P/E (13.9x vs 61.9x for Repligen). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | RGEN |
|---|---|---|
| Share price | $59.02 | $163.84 |
| Market cap | $14.62B | $10.40B |
| 1-day change | +0.99% | -2.02% |
| YTD return | +34.66% | -0.01% |
| 1-year return | +52.74% | +8.64% |
| 5-year return | +170.49% | -38.62% |
| P/E ratio (TTM) | 18.62 | 224.44 |
| Forward P/E | 13.92 | 61.88 |
| EPS (TTM) | $3.17 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $738.26M |
| Revenue growth (YoY) | +6.98% | +16.36% |
| Net income (latest FY) | $782.57M | $48.89M |
| Gross margin | 96.39% | 52.32% |
| Operating margin | 37.59% | 7.47% |
| Net margin | 33.73% | 6.62% |
| 52-week high | $61.14 | $198.87 |
| 52-week low | $33.76 | $100.99 |
| Distance from 52-week high | -3.47% | -17.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -7.61% | +18.99% |
| Average volume | 2.34M | 1.18M |
| Shares outstanding | 247.78M | 63.49M |
| Employees | 1,077 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed RGEN by 44.1 percentage points over the past year.
- Repligen trades at a higher earnings multiple (224.4x vs 18.6x trailing P/E).
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 6.6 cents for Repligen.
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
EXEL vs RGEN FAQ
Which is bigger, Exelixis or Repligen?
Exelixis (EXEL) is larger, with a market capitalization of $14.62B compared with $10.40B for Repligen (RGEN).
Which stock has performed better over the past year, EXEL or RGEN?
EXEL returned +52.74% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or RGEN?
EXEL has the lower trailing P/E at 18.6, versus 224.4 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Exelixis and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.